TLIS News and Press, Talis Biomedical Corporation From 05/11/23

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced a bus...

2023-03-22 17:07:36 ET Talis Biomedical press release ( NASDAQ: TLIS ): Q4 Revenue of $0.26M (-69.8% Y/Y) misses by $0.52M . Net loss was $26.9 million for the fourth quarter of 2022, compared to $28.7 million for the same period in 2021. Shares -3.31% AH. ...

REDWOOD CITY, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported fina...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Talis Biomedical press release ( NASDAQ: TLIS ): Q3 net loss was $26.0M for the third quarter of 2022, compared to $38.4M for the same period in 2021. Revenue of $0.8M (+300.0% Y/Y) beats by $0.49M . Unrestricted cash and cash equivalents on September 30, 2022, wer...

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Talis Biomedical Corporation (TLIS) Q2 2022 Earnings Conference Call August 01, 2022 04:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Roger Moody - Chie...

Talis Biomedical press release ( NASDAQ: TLIS ): Q2Revenue of $0.6M (+500.0% Y/Y) misses by $0.1M . Net loss was $27.0 million for the second quarter of 2022, compared to $64.5 million for the same period in 2021. For further details see: Talis Biomedical rep...

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business...